Washington, DC—Long-term follow-up of the MAINRITSAN trial confirmed primary results of the trial showing the superiority of rituximab compared with azathioprine as maintenance therapy for antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis. At 60 months, the rate of overall survival was 100% for rituximab versus 93% for azathioprine (P = .045). The rate of relapse-free survival was 57.9% versus 37.2%, respectively (P = .012).
Together with the European Renal Association−European Dialysis and Transplant Association (ERA-EDTA), the European League Against Rheumatism (EULAR) has published updated recommendations for the management of patients with antineutrophil cytoplasmic antibody−associated vasculitis.

Results 1 - 2 of 2
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology